Current Diagnosis and Future Impact of Micrometastases for Therapeutic Strategies in Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third

  • Asad Kutup
  • Emre F. Yekebas
  • Jakob R. IzbickiEmail author
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 182)


Esophageal and gastric cancers are aggressive neoplasms with a poor prognosis. Although postoperative mortality has declined and rates of complete resection have improved considerably, 5 year survival rates are still very low. Early metastatic relapse after complete resection of an apparently localized primary lesion indicates that disseminated tumor cells, undetectable by current methods, may already have been present at the time of surgery, even in patients with seemingly early tumor stages. Occult residual tumor disease is suggested when either bone marrow or lymph nodes from which tumor relapse may originate are affected by micrometastatic lesions undetectable by conventional histopath­o­logy. The presence of single tumor cells detected by immunohistological methods is increasingly regarded as a clinically relevant prognostic factor. The use of antibodies against tumor-associated targets enables detection of individual epithelial tumor cells in lymph nodes and in bone marrow in various tumor entities. The potential role and ­benefit of an antibody-based treatment as a therapeutic target would be of particular interest in tumors with a notoriously poor prognosis such as esophageal cancer and cardia cancer.


Esophageal Cancer Esophageal Carcinoma Esophagogastric Junction Disseminate Tumor Cell Cardia Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Akamatsu M, Matsumoto T, Oka K et al (2003) C-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57:1323–1327PubMedCrossRefGoogle Scholar
  2. Akiyama H, Tsurumaru M, Udagawa H et al (1994) Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220(3):364–372PubMedCrossRefGoogle Scholar
  3. al-Kasspooles M, Moore JH, Orringer MB et al (1993) Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54:213–219PubMedCrossRefGoogle Scholar
  4. Allgayer H, Babic R, Gruetzner KU et al (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18:2201–2209PubMedGoogle Scholar
  5. Baselga J, Tripathy D, Mendelsohn J et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78–83PubMedGoogle Scholar
  6. Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26(suppl 15):2–8PubMedGoogle Scholar
  7. Blot WJ, Devesa SS, Kneller RW et al (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289PubMedCrossRefGoogle Scholar
  8. Bogoevski D, Yekebas EF, Schurr P et al (2004) Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann Surg 240(6):993–1000PubMedCrossRefGoogle Scholar
  9. Bogoevski D, Onken F, Koenig A et al (2008) Is it time for a new TNM classification in esophageal carcinoma? Ann Surg Apr 247(4):633–641CrossRefGoogle Scholar
  10. Botterweck AA, Schouten LJ, Volovics A et al (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654PubMedCrossRefGoogle Scholar
  11. Brien TP, Odze RD, Sheehan CE et al (2000) HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol 31:35–39PubMedCrossRefGoogle Scholar
  12. Byrne J, Waldron R, McAvinchey D et al (1987) The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 13(5):409–411PubMedGoogle Scholar
  13. Bytzer P, Christensen PB, Damkier P et al (1999) Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study. Am J Gastroenterol 94:86–91PubMedCrossRefGoogle Scholar
  14. Casson AG, Rusch VW, Ginsberg RJ et al (1994) Lymph node mapping of esophageal cancer. Ann Thorac Surg 58:1569–1570PubMedCrossRefGoogle Scholar
  15. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053PubMedCrossRefGoogle Scholar
  16. Duhaylongsod FG, Gottfried MR, Iglehart JD et al (1995) The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 221:677–683PubMedCrossRefGoogle Scholar
  17. Flejou JF, Paraf F, Muzeau F et al (1994) Expression of c-erbB-2 oncogene product in Barrett’s adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 47:23–26PubMedCrossRefGoogle Scholar
  18. Friess H, Fukuda A, Tang WH et al (1999) Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 23:1010–1018PubMedCrossRefGoogle Scholar
  19. Geddert H, Zeriouh M, Wolter M et al (2002) Gene amplification and protein overexpression of c-erb-b2 in Barrett’s carcinoma and its precursor lesions. Am J Clin Pathol 118:60–66PubMedCrossRefGoogle Scholar
  20. Hardwick RH, Shepherd NA, Moorghen M et al (1995) c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett’s oesophagus. J Clin Pathol 48:129–132PubMedCrossRefGoogle Scholar
  21. Hardwick RH, Barham CP, Ozua P et al (1997) Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 23: 30–35PubMedCrossRefGoogle Scholar
  22. Hermanek P, Hutter RV, Sobin LH et al (1999) International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86(12):2668–2673PubMedCrossRefGoogle Scholar
  23. Hosch SB, Stoecklein NH, Pichlmeier U et al (2001) Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 19(7):1970–1975PubMedGoogle Scholar
  24. Ikeda Y, Ozawa S, Ando N et al (1996) Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. Ann Thorac Surg 62:835–838PubMedCrossRefGoogle Scholar
  25. Izbicki JR, Hosch SB, Pichlmeier U et al (1997) Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 337(17):1188–1194PubMedCrossRefGoogle Scholar
  26. Jankowski J, Coghill G, Hopwood D et al (1992) Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33:1033–1038PubMedCrossRefGoogle Scholar
  27. Jeon J, Luebeck EG, Moolgavkar SH (2006) Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control 17:971–981PubMedCrossRefGoogle Scholar
  28. Kasper M, Stosiek P, Typlt H et al (1987) Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol 23(2):137–147PubMedCrossRefGoogle Scholar
  29. Kim R, Clarke MR, Melhem MF et al (1997) Expression of p53, PCNA, and C-erbB-2 in Barrett’s metaplasia and adenocarcinoma. Dig Dis Sci 42:2453–2462PubMedCrossRefGoogle Scholar
  30. Koenig A, Prenzel KL, Bogoevski D et al (2009) Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 16:454–462PubMedCrossRefGoogle Scholar
  31. Kollmannsberger C, Pressler H, Mayer F et al (1999) Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody trastuzumab. Ann Oncol 10:1393–1394PubMedCrossRefGoogle Scholar
  32. Komukai S, Nishimaki T, Suzuki T et al (2002) Significance of immunohistochemical nodal micrometastasis as a prognostic indicator in potentially curable oesophageal carcinoma. Br J Surg 89(2):213–219PubMedGoogle Scholar
  33. Lam KY, Tin L, Ma L (1998) C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 24:431–435PubMedCrossRefGoogle Scholar
  34. Langer CJ, Stephenson P, Thor A et al (2004) Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 22:1180–1187PubMedCrossRefGoogle Scholar
  35. Latza U, Niedobitek G, Schwarting R et al (1990) Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 43(3):213–219PubMedCrossRefGoogle Scholar
  36. Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3:137–144PubMedCrossRefGoogle Scholar
  37. Locati LD, Rinaldi G, Bossi P et al (2005) Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 41:97–98PubMedCrossRefGoogle Scholar
  38. Maehara Y, Oshiro T, Endo K et al (1996) Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 119(4):397–402PubMedCrossRefGoogle Scholar
  39. Mimura K, Kono K, Hanawa M et al (2005) Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92:1253–1260PubMedCrossRefGoogle Scholar
  40. Momburg F, Moldenhauer G, Hammerling GJ et al (1987) Immunohistochemical study of the expression of a Mr 34, 000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47(11):2883–2891PubMedGoogle Scholar
  41. Mueller JD, Stein HJ, Oyang T et al (2000) Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction. Cancer 89(9):1874–1882PubMedCrossRefGoogle Scholar
  42. Nakamura T, Nekarda H, Hoelscher AH et al (1994) Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 73:1785–1794PubMedCrossRefGoogle Scholar
  43. Orengo MA, Casella C, Fontana V et al (2006) AIRT Working Group. Trends in incidence rates of oesophagus and gastric cancer in Italy by subsite and histology, 1986-1997. Eur J Gastroenterol Hepatol 18:739–746PubMedCrossRefGoogle Scholar
  44. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456PubMedCrossRefGoogle Scholar
  45. Pantel K, Schlimok G, Angstwurm M et al (1994) Methodological analysis of immunocyto­che­mical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3(3):165–173Google Scholar
  46. Parkin DM (2004) International variation. Oncogene 23:6329–6340PubMedCrossRefGoogle Scholar
  47. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(suppl 8):S4–S66Google Scholar
  48. Passlick B, Izbicki JR, Kubuschok B et al (1994) Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 12(9):1827–1832PubMedGoogle Scholar
  49. Persons DL, Croughan WS, Borelli KA et al (1998) Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 106:11–17PubMedCrossRefGoogle Scholar
  50. Polkowski W, van Sandick JW, Offerhaus GJ et al (1999) Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 6:290–297PubMedCrossRefGoogle Scholar
  51. Prenzel KL, Koenig A, Schneider PM et al (2007) Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol 14(2):954–959PubMedCrossRefGoogle Scholar
  52. Raymond WA, Leong AS (1989) Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathology; 21(1):11–5PubMedCrossRefGoogle Scholar
  53. Ross JS, McKenna BJ (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554–568PubMedCrossRefGoogle Scholar
  54. Safran H, Steinhoff M, Mangray S et al (2001) Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24:496–499PubMedCrossRefGoogle Scholar
  55. Safran H, DiPetrillo T, Nadeem A et al (2004) Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 22:670–677PubMedCrossRefGoogle Scholar
  56. Safran H, DiPetrillo T, Akerman P et al (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67(2):405–409PubMedCrossRefGoogle Scholar
  57. Sano T, Sasako M, Yamamoto S et al (2004) Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 22:2767–2773PubMedCrossRefGoogle Scholar
  58. Sauter ER, Keller SM, Erner S et al (1993) HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. Cancer Lett 75:41–44PubMedCrossRefGoogle Scholar
  59. Schurr PG, Yekebas EF, Kaifi JT et al (2006) Lymphatic spread and microinvolvement in ­adenocarcinoma of the esophago-gastric junction. J Surg Oncol 94(4):307–315PubMedCrossRefGoogle Scholar
  60. Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459PubMedCrossRefGoogle Scholar
  61. Siewert JR, Holscher AH, Becker K et al (1987) Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 58:25–32PubMedGoogle Scholar
  62. Siewert JR, Kestlmeier R, Busch R et al (1996) Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg 83(8):1144–1147PubMedCrossRefGoogle Scholar
  63. Suo Z, Holm R, Nesland JM (1992) Squamous cell carcinomas, an immunohistochemical and ultrastructural study. Anticancer Res 12:2025–2031PubMedGoogle Scholar
  64. Suo Z, Su W, Holm R et al (1995) Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res 15:2797–2798PubMedGoogle Scholar
  65. Suwanagool P, Parichatikanond P, Maeda S (1993) Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study. Asian Pac J Allergy Immunol 11:119–122PubMedGoogle Scholar
  66. Tanaka S, Mori M, Akiyoshi T et al (1997) Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Res 57:28–31PubMedGoogle Scholar
  67. Tripathy D, Slamon DJ, Cobleigh M et al (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063–1070PubMedCrossRefGoogle Scholar
  68. Trivers KF, Sabatino SA, Stewart SL (2008) Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 123(6):1422–1428PubMedCrossRefGoogle Scholar
  69. Trudgill NJ, Suvarna SK, Royds JA et al (2003) Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction. Mol Pathol 56:313–317PubMedCrossRefGoogle Scholar
  70. Tuma RS (2005) Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 97:870–871PubMedCrossRefGoogle Scholar
  71. Vizcaino AP, Moreno V, Lambert R et al (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99:860–868PubMedCrossRefGoogle Scholar
  72. Walch A, Bink K, Gais P et al (2000a) Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett’s adenocarcinoma. Anal Cell Pathol 20:25–32PubMedGoogle Scholar
  73. Walch AK, Zitzelsberger HF, Bink K et al (2000b) Molecular genetic changes in metastatic primary Barrett’s adenocarcinoma and related lymph node metastases: comparison with nonmetastatic Barrett’s adenocarcinoma. Mod Pathol 13:814–824PubMedCrossRefGoogle Scholar
  74. Walch A, Specht K, Bink K et al (2001) Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett’s esophagus. Lab Invest 81:791–801PubMedCrossRefGoogle Scholar
  75. Walther C, Zilling T, Perfekt R et al (2001) Increasing prevalence of adenocarcinoma of the oesophagus and gastro-oesophageal junction: a study of the Swedish population between 1970 and 1997. Eur J Surg 167:748–757PubMedCrossRefGoogle Scholar
  76. Waterman TA, Hagen JA, Peters JH et al (2004) The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 78(4):1161–1169PubMedCrossRefGoogle Scholar
  77. Z’Graggen K, Centeno BA, Fernandez-del Castillo C et al (2001) Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery 129(5):537–546PubMedCrossRefGoogle Scholar
  78. Zhang D, Salto-Tellez M, Do E et al (2003) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34:362–368PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of General, Visceral and Thoracic SurgeryUniversity Hospital Hamburg EppendorfHamburgGermany

Personalised recommendations